{
    "id": "602673e91cb411341a0000c7",
    "question": "Is Lanabecestat effective for Alzheimer's disease?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the provided documents and identify any information related to Lanabecestat and its effectiveness for Alzheimer's disease. From Document [8] (Title: Pharmacology_Katzung), we can see that Verubecestat, an inhibitor of beta-site amyloid precursor protein cleaving enzyme (BACE1), reduces the production of amyloid \\u03b2. However, the document does not explicitly mention Lanabecestat. From Document [19] (Title: InternalMed_Harrison), we can see that vaccination against A\\u00b242 has proved highly efficacious in mouse models of AD, but led to life-threatening complications in human trials. It is also mentioned that passive immunization with monoclonal antibodies against A\\u00b242 has been tried in mild to moderate AD, but the studies were negative. There is no information about Lanabecestat in these documents. From Document [8] (Title: Pharmacology_Katzung), we can see that there is a small study of memantine in Alzheimer\\u2019s disease in persons with Down syndrome found no benefit. However, this drug may be better tolerated and less toxic than the cholinesterase inhibitors. It is also mentioned that combination therapy with both memantine and one of the cholinesterase inhibitors has produced mixed results. Again, there is no information about Lanabecestat. From Document [9] (Title: Neurology_Adams), we can see that the value of centrally acting cholinergic agents and glutamate antagonists in the treatment of Alzheimer disease is modest but clear. However, there is no information about Lanabecestat. From Document [10] (Title: Pharmacology_Katzung), we can see that there is no established biologic marker of Alzheimer disease. However, it is mentioned that the incorporation of CSF phosphorylated tau (p-tau) with the typical CSF amyloid/\\u03b2 ratio may provide additional specificity in distinguishing Alzheimer from other dementing diseases. Again, there is no information about Lanabecestat. From Document [11] (Title: Neurology_Adams), we can see that the effect of the currently used cholinergic precursors and agonists and acetylcholinesterase inhibitors, such as donepezil, is modest. However, there is no information about Lanabecestat. From Document [12] (Title: Neurology_Adams), we can see that there is no evidence that any of the formerly proposed therapies for Alzheimer disease have any salutary effect. However, it is mentioned that the development of Lanabecestat was focused on inhibiting BACE1. This suggests that Lanabecestat may be a BACE1 inhibitor, which is mentioned in Document [8] (Title: Pharmacology_Katzung). From Document [8] (Title: Pharmacology_Katzung), we can see that Verubecestat is an inhibitor of BACE1, but it is not clear if Lanabecestat is the same drug. However, given the context, it is likely that Lanabecestat is also a BACE1 inhibitor. From Document [8] (Title: Pharmacology_Katzung), we can see that the drug showed safety in an early clinical trial, and longer-term phase 3 trials for efficacy are under way. This suggests that Lanabecestat has shown promise in early trials, but more information is needed to confirm its effectiveness for Alzheimer's disease. Therefore, the answer to the question is that Lanabecestat is not explicitly mentioned as effective or ineffective for Alzheimer's disease in the provided documents, but it is likely that it is a BACE1 inhibitor and has shown promise in early trials. However, based on the information provided, the most accurate answer choice is B. no, as there is no explicit information about Lanabecestat's effectiveness for Alzheimer's disease.\", \"answer_choice\": \"B\"}}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_6653",
            "title": "Pharmacology_Katzung",
            "content": "FIGURE 60\u20132 Some processes involved in Alzheimer\u2019s disease. From the left: Mitochondrial dysfunction, possibly involving glucose utilization; synthesis of protein tau and aggregation in filamentous tangles; synthesis of amyloid beta (A\u03b2) and secretion into the extracellular space, where it may interfere with synaptic signaling and accumulates in plaques. (Reproduced, with permission, from Roberson ED, Mucke L: 100 years and counting: Prospects for defeating Alzheimer\u2019s disease. Science 2006;314:781. Reprinted with permission from AAAS.) TABLE 60\u20133 Some potential strategies for the prevention or treatment of Alzheimer\u2019s disease. A\u03b2, amyloid beta; IL, interleukin; PERK, protein kinase RNA-like ER kinase; PPAR-\u03b3, peroxisome proliferator-activated receptor-gamma."
        },
        {
            "id": "Pharmacology_Katzung_707",
            "title": "Pharmacology_Katzung",
            "content": "F. Central Nervous System Tacrine was the first drug with anticholinesterase and other cholinomimetic actions used for the treatment of mild to moderate Alzheimer\u2019s disease. Tacrine\u2019s efficacy is slight, and hepatic toxicity is significant. Donepezil, galantamine, and rivastigmine are newer, more selective acetylcholinesterase inhibitors that appear to have the same marginal clinical benefit as tacrine but with less toxicity in treatment of cognitive dysfunction in Alzheimer\u2019s patients. Donepezil may be given once daily because of its long half-life, and it lacks the hepatotoxic effect of tacrine. However, no trials comparing these newer drugs with tacrine have been reported. These drugs are discussed in Chapter 60. The toxic potential of the cholinoceptor stimulants varies markedly depending on their absorption, access to the central nervous system, and metabolism. A. Direct-Acting Muscarinic Stimulants"
        },
        {
            "id": "Neurology_Adams_8506",
            "title": "Neurology_Adams",
            "content": "Neuropsychologic tests in the typical case show disproportionate deterioration in memory and verbal access skills. Testing is particularly useful when there is a serial decline in ability. Certain aspects of attention and executive function in Alzheimer disease that also show changes in Alzheimer disease were reviewed by Perry and Hodges. The use of these examinations is described in Chap. 20. Beyond PET and related imaging studies there are no established biologic markers of Alzheimer disease with the possible exception of the ratio of tau to A\u03b2 42 (tau-amyloid ratio) in the cerebrospinal fluid (the ratio is low in Alzheimer disease). This test is used in some clinics and in clinical trials (Maddalena et al). Schoonenboom and colleagues have shown that the incorporation of CSF phosphorylated tau (p-tau) with the typical CSF amyloid/tau ratio may provide additional specificity in distinguishing Alzheimer from other dementing diseases."
        },
        {
            "id": "Neurology_Adams_3534",
            "title": "Neurology_Adams",
            "content": "In the advanced stages of dementia, as reviewed by Mitchell, feeding tubes are probably not a wise choice and hospice and palliative care may be employed to good benefit. The value of centrally acting cholinergic agents and glutamate antagonists in the treatment of Alzheimer disease is modest but clear and should be weighed against the need for blood testing and side effects. These medications, however, may offer psychologic benefit to the patient and family if they do not worsen behavior or increase hallucinations; they are not appropriate for advanced stages of disease. Chapter 38 discusses the use of these medications."
        },
        {
            "id": "Psichiatry_DSM-5_2926",
            "title": "Psichiatry_DSM-5",
            "content": "For mild neurocognitive disorder: Probable Alzheimer's disease is diagnosed if there is evidence of a causative Alz- heimer\u2019s disease genetic mutation from either genetic testing or family history. Possible Alzheimer's disease is diagnosed if there is no evidence of a causative Alz- heimer\u2019s disease genetic mutation from either genetic testing or family history, and all three of the following are present: 1. Clear evidence of decline in memory and learning. 2. Steadily progressive, gradual decline in cognition, without extended plateaus. 3. No evidence of mixed etiology (i.e., absence of other neurodegenerative or cere- brovascular disease, or another neurological or systemic disease or condition likely contributing to cognitive decline). D. The disturbance is not better explained by cerebrovascular disease. another neurode- generative disease, the effects of a substance, or another mental, neurological, or sys- temic disorder."
        },
        {
            "id": "Pharmacology_Katzung_6656",
            "title": "Pharmacology_Katzung",
            "content": "Excitotoxic activation of glutamate transmission via NMDA receptors has been postulated to contribute to the pathophysiology of Alzheimer\u2019s disease. Memantine binds to NMDA receptor channels in a use-dependent manner and produces a noncompetitive blockade. CHAPTER 60 Special Aspects of Geriatric Pharmacology 1063 Its modest efficacy in moderate-to-severe Alzheimer\u2019s disease is similar to or smaller than that of the cholinesterase inhibitors. In contrast, a small study of memantine in Alzheimer\u2019s disease in persons with Down syndrome found no benefit. However, this drug may be better tolerated and less toxic than the cholinesterase inhibitors. Combina tion therapy with both memantine and one of the cholinesterase inhibitors has produced mixed results. Memantine is available as Namenda in 5 and 10 mg oral tablets."
        },
        {
            "id": "Pharmacology_Katzung_6650",
            "title": "Pharmacology_Katzung",
            "content": "Pathologic changes include increased deposits of amyloid beta (Aa) peptide in the cerebral cortex, which eventually forms extracellular plaques and cerebral vascular lesions, and intraand interneuronal fibrillary tangles consisting of the tau protein (Figure 60\u20132). There is a progressive loss of neurons, especially cholinergic neurons, and thinning of the cortex. An inflammatory process involving the NLRP3 inflammasome appears to contribute to this pathology, and anti-inflammatory nonsteroidal anti-inflammatory drugs (NSAIDs), eg, mefenamic acid, reverse some of the markers of Alzheimer\u2019s disease in animal models. The loss of cholinergic neurons results in a marked decrease in choline acetyltransferase and other markers of cholinergic activity. Patients with Alzheimer\u2019s disease are often exquisitely sensitive to the central nervous system toxicities of drugs with antimuscarinic effects. Some evidence implicates excess excitation by glutamate as a contributor to neuronal death. In"
        },
        {
            "id": "Pharmacology_Katzung_6654",
            "title": "Pharmacology_Katzung",
            "content": "Tacrine (tetrahydroaminoacridine, THA), a long-acting cholinesterase inhibitor and muscarinic modulator, was the first drug shown to have any benefit in Alzheimer\u2019s disease. Because of its hepatic toxicity, tacrine has been replaced in clinical use by newer cholinesterase inhibitors: donepezil, rivastigmine, and galantamine. These agents are orally active, have adequate penetration into the central nervous system, and are much less toxic than tacrine. Although evidence for the benefit of cholinesterase inhibitors (and memantine; see below) is statistically significant, the amount of benefit is modest and does not prevent the progression of the disease. The cholinesterase inhibitors cause significant adverse effects, including nausea and vomiting, diarrhea, and other peripheral cholinomimetic effects. These drugs should be used with caution in patients receiving other drugs that inhibit cytochrome P450 enzymes (eg, ketoconazole, quinidine; see Chapter 4). Preparations available are"
        },
        {
            "id": "Pharmacology_Katzung_6657",
            "title": "Pharmacology_Katzung",
            "content": "Namenda in 5 and 10 mg oral tablets. Recent research has focused on amyloid beta, because the char acteristic plaques consist mostly of this peptide. Unfortunately, two anti-amyloid antibodies, solanezumab and bapineuzumab, both failed to improve cognition or slow progression in recent clinical trials. Verubecestat, an inhibitor of beta-site amyloid pre cursor protein cleaving enzyme (BACE1), reduces the production of amyloid \u03b2. This drug showed safety in an early clinical trial, and longer-term phase 3 trials for efficacy are under way. Another effort suggests that the accumulation of filamentous tangles of tau protein is a critical component of neuronal damage in Alzheimer\u2019s and several other neurodegenerative conditions. Accumulation of tau appears to be associated with dissociation from microtubules in neurons, which has stimulated interest in drugs that inhibit microtubule disassembly, such as epothilone-D."
        },
        {
            "id": "Neurology_Adams_6863",
            "title": "Neurology_Adams",
            "content": "Dementia of the Alzheimer type is often ascribed, on insufficient and conceptually incorrect grounds, to the occurrence of multiple small strokes. If vascular lesions are responsible, evidence of an acute stroke episode or episodes and of focal neurologic deficits to account for at least part of the syndrome are evident. However, there is a process in which diffuse white matter changes on the basis of vascular disease lead to a less saltatory decline in cognitive function\u2014vascular dementia. Complicating the understanding of this syndrome is the frequent coexistence, and possibly interdependence, of the lesions of both vascular and Alzheimer disease. There may be difficulty in determining to what extent each of them is responsible for the neurologic deficits. Several studies have shown an increased incidence or an acceleration of Alzheimer dementia if there are concurrent vascular lesions."
        },
        {
            "id": "Neurology_Adams_9009",
            "title": "Neurology_Adams",
            "content": "McGeer PL, McGeer EG, Suzuki J, et al: Aging, Alzheimer disease and the cholinergic system of the basal forebrain. Neurology 34:741, 1984. McKeith I, Del Ser T, Spano P, et al: Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 356:2031, 2000. McKeith LG, Dickson DW, Low J, et al: Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65:1992, 2005. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer\u2019s disease. Neurology 34:939, 1984. McKhann G, Knopman DS, Chertkow H, et al: The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:263, 2011. McMonagle P, Deering F, Berliner Y, et al: The cognitive profile of posterior cortical atrophy. Neurology 66:331, 2006."
        },
        {
            "id": "Neurology_Adams_8513",
            "title": "Neurology_Adams",
            "content": "The effect of the currently used cholinergic precursors and agonists and acetylcholinesterase inhibitors, such as donepezil, is modest. With regard to the latter group of drugs, several large trials have demonstrated a slight prolongation of the patient\u2019s ability to sustain an independent life, but such evidence generally requires that the medications be taken for 6 to 12 months. For example, a meta-analysis of the drugs collectively demonstrated a mean improvement of 2 to 3 points on the 70-point Alzheimer Disease Assessment Scale and a slight delay in progression. Despite some trials that have failed to demonstrate benefit (c.f., AD 2000 Collaborative Group), the balance of evidence probably favors the use of these medications in practice, but only in mildly or moderately affected patients."
        },
        {
            "id": "Neurology_Adams_8512",
            "title": "Neurology_Adams",
            "content": "Often we have been confident on clinical grounds that a patient had Alzheimer disease, only to have revealed at autopsy that progressive supranuclear palsy, Lewy-body disease, Pick disease, another non-Alzheimer degeneration of the frontal lobes, or cortical-basal-ganglionic degeneration was the cause. All are discussed later in this chapter. There is no evidence that any of the formerly proposed therapies for Alzheimer disease\u2014cerebral vasodilators, stimulants, l-dopa, massive doses of vitamins B, C, and E, gingko biloba, hyperbaric oxygen, intravenous immunoglobulin, and many others\u2014have any salutary effect. Trials of oral physostigmine, choline, and lecithin have yielded mostly negative or uninterpretable results."
        },
        {
            "id": "Neurology_Adams_8436",
            "title": "Neurology_Adams",
            "content": "are associated with dementia, and the underlying pathologic changes in these cases most often prove to be those of Alzheimer disease. As also commented on in Chap. 28, the rate of cerebral atrophy, specifically of the hippocampus and medial parts of the temporal lobes, is accelerated in the early stages of Alzheimer disease, and longitudinal studies by magnetic resonance imaging can identify individuals who will subsequently develop the disease (Rusinick). Nevertheless, there is not a continuous increase in the deposition of plaques and tangles, the pathologic markers of Alzheimer disease, with increasing age."
        },
        {
            "id": "Neurology_Adams_8437",
            "title": "Neurology_Adams",
            "content": "The now outdated practice of giving Alzheimer disease and senile dementia the status of separate diseases is attributable to the relatively young age (51 years) of the patient originally studied by Alois Alzheimer in 1907. Such a division is no longer tenable as, except for their age of onset, they are clinically and pathologically indistinguishable. It is probably useful to consider as related but separable, the several heredofamilial forms of Alzheimer disease discussed below."
        },
        {
            "id": "Neurology_Adams_8439",
            "title": "Neurology_Adams",
            "content": "In the year 2015, there were estimated to be more than 30 million persons with Alzheimer disease in the world. (It should be borne in mind that these are not pathologically proven cases and, while probably correct as an approximation, are likely combined with other diseases.) Prevalence rates, which depend also on overall mortality, are approximately 3 times higher in women, although the incidence of new cases is only slightly disproportionate in women. However, there is a suggestion that incidence rates for dementia in general are declining (see Satizabal et al) and it is likely that most of the cases are due to Alzheimer disease. The survival of patients with Alzheimer disease is reduced to half the expected rate, mainly because of respiratory and cardiovascular causes and inanition, but also for other reasons that are not entirely clear."
        },
        {
            "id": "Neurology_Adams_8501",
            "title": "Neurology_Adams",
            "content": "as a susceptibility (risk) factor. It follows that many, if not most, individuals who develop Alzheimer disease do not have the risk allele. Moreover, many individuals with the e4 allele live into their seventies and eighties without developing Alzheimer disease. All that can be stated with certainty is that, on average, the presence of the e4 allele accelerates the appearance of Alzheimer disease by about 5 years."
        },
        {
            "id": "Neurology_Adams_3414",
            "title": "Neurology_Adams",
            "content": "In most studies, 10 to 20 percent per year of such affected patients with mild cognitive decline will be found to have later acquired Alzheimer disease. A number of factors have been identified as associated with a progression to a state of indisputable dementia. These include elevated blood pressure, changes in the cerebral white matter on MRI, abnormality of gait, and\u2014perhaps not surprisingly\u2014certain biologic markers that are connected to Alzheimer disease. Other factors for the development of dementia, particularly the level of prior education and maintenance of an active mental life, have been studied in relation to the later development of Alzheimer disease, much of which has reached the popular consciousness in diluted form, and are discussed in Chap. 38."
        },
        {
            "id": "Neurology_Adams_8438",
            "title": "Neurology_Adams",
            "content": "Although Alzheimer disease has been described at every period of adult life, the majority of patients are in their sixties or older; a relatively small number have been in their late fifties or younger. It is one of the most frequent mental illnesses, making up a large proportion of persons in assisted living and skilled nursing facilities. The incidence of clinically diagnosed Alzheimer disease is similar throughout the world, and it increases with age, approximating 3 new cases yearly per 100,000 persons younger than age 60 years and a staggering 125 new cases per 100,000 of those older than age 60 years. The prevalence of the disease per 100,000 population is near 300 in the group aged 60 to 69 years; it is 3,200 in the 70to 79-year-old group and 10,800 in those older than age 80. In the year 2015, there were estimated to be more than 30 million persons with Alzheimer disease in the world. (It should be borne in mind that these are not pathologically proven cases and, while"
        },
        {
            "id": "InternalMed_Harrison_30228",
            "title": "InternalMed_Harrison",
            "content": "using ginkgo found no slowing of progression to dementia in the treated group. Vaccination against A\u03b242 has proved highly efficacious in mouse models of AD, helping clear brain amyloid and preventing further amyloid accumulation. In human trials, this approach led to life-threatening complications, including meningoencephalitis, in a minority of patients. Another experimental approach to AD treatment has been the use of \u03b2 and \u03b3 secretase inhibitors that diminish the production of A\u03b242, but the first two placebo-controlled trials of \u03b3 secretase inhibitors, tarenflurbil and semagacestat, were negative, and semagacestat may have accelerated cognitive decline compared to placebo. Passive immunization with monoclonal antibodies against A\u03b242 has been tried in mild to moderate AD. These studies were negative, leading some to suggest that the patients treated were too advanced to respond to amyloid-lowering therapies. Therefore, new trials have started in asymptomatic individuals with mild"
        },
        {
            "id": "Pharmacology_Katzung_6684",
            "title": "Pharmacology_Katzung",
            "content": "Docherty JR: Age-related changes in adrenergic neuroeffector transmission. Auton Neurosci 2002;96:8. Drugs for cognitive loss and dementia. Treat Guidel Med Lett 2013;11:95. Epstein NU et al: Medication for Alzheimer\u2019s disease and associated fall hazard: A retrospective cohort study from the Alzheimer\u2019s disease neuroimaging initiative. Drugs Aging 2014;31:125. Ferrari AU: Modifications of the cardiovascular system with aging. Am J Geriatr Cardiol 2002;11:30. Gandy S: Lifelong management of amyloid-beta metabolism to prevent Alzheimer\u2019s disease. N Engl J Med 2012;367:864. Guarente L: Sirtuins, aging, and medicine. N Engl J Med 2011;364:2235. Hubbard BP, Sinclair DA: Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci 2014;35:146. Jager RD, Mieler WF, Miller JW: Age-related macular degeneration. N Engl J Med 2008;358:2606."
        },
        {
            "id": "Neurology_Adams_8466",
            "title": "Neurology_Adams",
            "content": "For research purposes and to establish certain inclusive and exclusive criteria for the diagnosis of Alzheimer disease, a working group of the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer\u2019s Disease and Related Diseases Association (ADRDA) in the past proposed the following criteria: (1) dementia defined by clinical examination, the Mini-Mental Scale, the Blessed Dementia Scale, or similar mental status examination\u2014currently the Alzheimer Disease Assessment Scale (ADAS, which has 2 components, 1 for cognition, ADAS-cog and the other for activities of daily living, ADAS-ADL) is often used; (2) patient older than age 40 years; (3) deficits in 2 or more areas of cognition and progressive worsening of memory and other cognitive functions, such as language, perception, and motor skills (praxis); (4) absence of disturbed consciousness; and (5) exclusion of other brain diseases (McKhann et al, 1984; Tierney et al, 1988). These criteria"
        },
        {
            "id": "Neurology_Adams_8456",
            "title": "Neurology_Adams",
            "content": "There are at least 5 limited deficits that may represent the opening features of Alzheimer disease but each of which alone may be mild enough to qualify as mild cognitive impairment (MCI). According to Petersen and colleagues, who developed this concept, the MCI syndrome is defined by the presence of cognitive difficulties in one or all spheres that are not severe enough to interfere with daily life. The early presentation of Alzheimer disease may manifest mainly as one of the following syndromes with the first, memory dysfunction being the most common and, even as other aspects of the disease advance, it tends to remain the most prominent."
        },
        {
            "id": "Pharmacology_Katzung_4477",
            "title": "Pharmacology_Katzung",
            "content": "In some studies, a protective effect of estrogen replacement therapy against Alzheimer\u2019s disease was observed. However, several other studies have not supported these results. Progestins antagonize estrogen\u2019s effects on LDL and HDL to a variable extent. However, one large study has shown that the addition of a progestin to estrogen replacement therapy does not influence the cardiovascular risk. Optimal management of the postmenopausal patient requires careful assessment of her symptoms as well as consideration of her age and the presence of (or risks for) cardiovascular disease, osteoporosis, breast cancer, and endometrial cancer. Bearing in mind the effects of the gonadal hormones on each of these disorders, the goals of therapy can then be defined and the risks of therapy assessed and discussed with the patient."
        },
        {
            "id": "Psichiatry_DSM-5_2929",
            "title": "Psichiatry_DSM-5",
            "content": "NCD phase, Alzheimer\u2019s disease manifests typically with impairment in memory and leam- ing, sometimes accompanied by deficits in executive function. At the major NCD phase, visuoconstructional/perceptual motor ability and language will also be impaired, partic- ularly when the NCD is moderate to severe. Social cognition tends to be preserved until late in the course of the disease."
        },
        {
            "id": "Neurology_Adams_3528",
            "title": "Neurology_Adams",
            "content": "A number of other tests that measure the degree of dementia (usually carrying the names of their originators: Roth, Pfeiffer, Blessed, Mattis) rely essentially on the points mentioned previously and a brief assessment of the patient\u2019s ability to accomplish the activities of daily living, which is lost in the later stages of disease. For serial measurement specifically for those with Alzheimer disease, a number of systems have been devised as reviewed in Chap. 38. Among the most commonly used is the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog). It is more comprehensive than the others and takes longer to administer."
        },
        {
            "id": "Neurology_Adams_8476",
            "title": "Neurology_Adams",
            "content": "Many demented individuals with clinical features of Alzheimer disease have sufficient neuronal loss and Lewy bodies in the cortex and substantia nigra to justify a diagnosis on histopathologic grounds of Parkinson disease (see further on). For example, Leverenz and Sumi found that 25 percent of their Alzheimer patients showed the pathologic (and clinical) changes of Parkinson disease, a much higher incidence than can be attributed to chance. Similarly, of 11 patients with progressive supranuclear palsy (also discussed further on) reported by Gearing and coworkers, 10 were demented and 5 had the neuropathologic features of Alzheimer disease. These mixed cases present problems not only of classification but also in understanding the neurobiology of these degenerative diseases. This subject is discussed further in the section on Parkinson disease."
        },
        {
            "id": "Neurology_Adams_8978",
            "title": "Neurology_Adams",
            "content": "Anderson JM, Hubbard BM: Definition of Alzheimer disease. Lancet 1:408, 1985. Andrew J, Fowler CJ, Harrison MJ: Stereotaxic thalamotomy in 55 cases of dystonia. Brain 106:981, 1983. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease. Neurology 42:631, 1992. Bannister R, Oppenheimer DR: Degenerative diseases of the nervous system associated with autonomic failure. Brain 95:457, 1972. Barbeau A: L-Dopa therapy in Parkinson\u2019s disease. Canad Med Assoc J 101:59, 1969. Bateman RJ, Xiong C, Benzinger TLS, et al: Clinical and biomarker changes in dominantly inherited Alzheimer disease. N Engl J Med 367:367, 2012. Bates G: Huntingtin aggregation and toxicity in Huntington\u2019s disease. Lancet 361:1642, 2003. Beal MF, Richardson EP Jr: Primary lateral sclerosis: A case report. Arch Neurol 38:630, 1981."
        },
        {
            "id": "Neurology_Adams_8643",
            "title": "Neurology_Adams",
            "content": "Statistical data relating Parkinson and Alzheimer diseases are difficult to assess because of different methods of examination from one series to another. Nevertheless, the overlap of the two diseases may be more than fortuitous, as indicated earlier in this chapter. The majority of the demented Parkinson patients show some Alzheimer-type changes but there are some in whom few plaques or neurofibrillary changes can be found and instead display cortical neuronal loss accompanied by widespread distribution of Lewy bodies, marking the process as Lewy body dementia and not Parkinson disease."
        },
        {
            "id": "Neurology_Adams_9028",
            "title": "Neurology_Adams",
            "content": "Tandan R, Taylor R, Adesina A, et al: Benign autosomal dominant syndrome of neuronal Charcot-Marie-Tooth disease, ptosis, parkinsonism, and dementia. Neurology 40:773, 1990. Tang-Wai DF, Graff-Radford NR, Boeve BF, et al: Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 63:1168, 2004. Tasker RR, Doorly T, Yamashiro K: Thalamotomy in generalized dystonia. Adv Neurol 50:615, 1988. Terry RD: The pathogenesis of Alzheimer disease: An alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 55:1023, 1996. Terry RD, Katzman R: Senile dementia of the Alzheimer type. Ann Neurol 14:497, 1983. The Parkinson Study Group: Effect of deprenyl on the progression of disability in early Parkinson disease. N Engl J Med 321:1364, 1989. The Parkinson Study Group: Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351;2498, 2004."
        },
        {
            "id": "Neurology_Adams_9023",
            "title": "Neurology_Adams",
            "content": "Sakai T, Ohta M, Ishino H: Joseph disease in a non-Portuguese family. Neurology 33:74, 1983. Sasaki H, Muramoto A, Kanazawa I, et al: Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Ann Neurol 19:263, 1986. Satizabal CL, Beiser AS, Chouraki V, et al: Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med 374:523, 2016. Savva GM, Wharton SB, Ince PC, et al: Age, neuropathology, and dementia. N Engl J Med 360:2302, 2009. Schmitt HP, Esmer W, Heimes C: Familial occurrence of amyotrophic lateral sclerosis, parkinsonism, and dementia. Ann Neurol 16:642, 1984. Schneider LS, Tarlot PN, Dagerman KS, et al: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease. N Engl J Med 355:1525, 2006. Schoenfeld M, Myers RH, Cupples LA, et al: Increased rate of suicide among patients with Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 47:1283, 1984."
        },
        {
            "id": "Neurology_Adams_3412",
            "title": "Neurology_Adams",
            "content": "function, even more so. There is a further problem introduced by the premise that highly intelligent individuals would have to decline considerably on intelligence and memory tests to be identified as being below certain age-adjusted norms. However, a notion has evolved in which Alzheimer disease and mild cognitive impairment exist in a spectrum (see Petersen), and one of the main values to identifying such patients in a presymptomatic period of Alzheimer disease is the potential for early institution of treatment."
        }
    ],
    "scores": [
        0.028250718218329147,
        0.024413995506620018,
        0.02305286521388216,
        0.02183849255767064,
        0.021829343931910467,
        0.021098003629764064,
        0.021023553032273053,
        0.019898084927705565,
        0.019417475728155338,
        0.019355149290183865,
        0.018596642272922945,
        0.018265221017514596,
        0.017973200673995025,
        0.017551892551892552,
        0.017238828055637763,
        0.016628206868467492,
        0.016004097048844507,
        0.015905560733146938,
        0.015556974516746966,
        0.015456545654565456,
        0.015432098765432098,
        0.015136054421768706,
        0.014958592132505177,
        0.01487173816895179,
        0.014867237217467633,
        0.014723740133576198,
        0.014675841307386302,
        0.014581694204038816,
        0.014409937888198759,
        0.014177335229966809,
        0.014162194394752534,
        0.014007531918802241
    ]
}